UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing (Q45374139)

13 December 2017

0 references

UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing (English)

1 reference

13 December 2017

0 references

1 reference

1 reference

1

1 reference

13 December 2017

15 January 2008

1 reference

13 December 2017

1 reference

13 December 2017

26

1 reference

13 December 2017

6

1 reference

13 December 2017

646-651

1 reference

DNA-based molecular cytology for bladder cancer surveillance

13 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Aneuploidy in bladder cancers: the utility of fluorescent in situ hybridization in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Re: Mecedes Marín-Aguilera, Lourdes Mengual, María José Ribal et al. Utility of Fluorescence In Situ Hybridization as a Non-invasive Technique in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma. Eur Urol 2007;51:409–15 and Alan M. Nied

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Meta-DiSc: a software for meta-analysis of test accuracy data.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Application of multiplex FISH, CGH and MSSCP techniques for cytogenetic and molecular analysis of transitional cell carcinoma (TCC) cells in voided urine specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Diagnostic tests 4: likelihood ratios

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Ruling a diagnosis in or out with "SpPIn" and "SnNOut": a note of caution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.06.002

10.1016/J.UROLONC.2007.06.002

7 January 2021

Identifiers

DOI

1 reference

release_2cdfpj72djccre5b4zcmlryw6m

13 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2cdfpj72djccre5b4zcmlryw6m

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

18367109

1 reference

PubMed ID

18367109